Gilead Stock Crashed Despite Potential Cure for COVID-19! Buy or Sell?

Gilead stock (GILD) crashed despite the breaking positive news on April 20th which suggested they may have a potential cure for the COVID-19 which is caused by the new coronavirus. Should you consider buying the Gilead Sciences stock? If so, should you buy Gilead now or wait a bit longer? Once you buy, should you hold GILD stock long term to take advantage of the Gilead dividend payments, or should you take profit early at key resistance levels? More importantly, what type of investor should consider adding Gilead to their portfolio? Investors with high-risk appetite? Medium or low-risk appetite? This is certainly among my stocks to watch.

I’m going to conduct my Invest Diva diamond analysis or the IDDA for potential investment strategies for the Gilead stock.

New to investing? Start off the right way >>

Gilead Stock Price Analysis – Fundamentals

Gilead’s antiviral drug was tested to treat Ebola patients — now it’s the most promising potential COVID-19 treatment. More specifically, the University of Chicago Medicine Hospital, where patients are participating in Gilead-sponsored remdesivir trials. Out of 125 coronavirus-infected patients who participated, 113 had severe symptoms. Most patients recovered in less than a week and 2 died. That’s a 1.6% death rate compared to the 4.9% overall US rate

Despite this, Gilead is not yet in my top ten must-haves in the Invest Diva’s premium investing group  (PIG).

You might also like: Tesla Stock Price Analysis 2020 | Is TSLA Still A Good Buy Or Did You Miss Out?

Gilead Stock Technical Analysis – Weekly Chart

Everything I’m saying right now is purely my personal opinion. investing in the stock market and your other market involves a risk of loss and you should only trade the money that you can afford to lose. with that let’s take a look at the chart of GILD or Gilead stock. if we zoom out you’ll notice that Gilead has actually had a very nice growth since 1999 and which is high as high at $122 in 2015.

ever since it is actually broken below the Ichimoku cloud and it currently appears to be in the process of forming a double bottom bullish reversal chart pattern. so purely from a technical point of view, we can see that the bearish momentum may be coming to an end. if you look at the weekly chart you’ll notice
that it has already broken above the Ichimoku cloud. Check out my book Ichimoku Secrets.

normally when a stock or any kind of asset price breaks above an Ichimoku cloud we expected to have a pullback towards the upper band of the Ichimoku cloud.

Gilead Stock Technical Analysis – Daily Chart

on the daily chart it broke  above the Ichimoku cloud after consolidating for quite a while in 2019. after that, of course, the
fundamentals of the situation changed. but after breaking a key resistance level at 84 which in fact was the 38% Fibonacci retracement level it is now
finally pulling back towards the Ichimoku cloud. the Fibonacci retracement level is tracking the downtrend from the highest high of 122 towards the lowest low of 60.

the combination of this shows that we could certainly from a technical point of view expect further gains for the Gilead stock but we will see further drops towards the upper band of at least the daily Ichimoku cloud which is here at around 74.

How To  Take Control Of Your Financial Future >>

VIDEOS YOU’LL LOVE

CrowdStrike Stock (CRWD): The Move No One Is Talking About But Everyone Should Watch

CrowdStrike is one of the biggest names in cybersecurity. They protect computers, cloud systems, and now even AI models. The company keeps growing fast, keeps making moves with giants like Nvidia and Google, and keeps expanding its platform into places most investors are not watching yet.

That is why this blog exists. There is a lot happening behind the scenes with CrowdStrike. Some of it is obvious. Some of it is quiet. Some of it could shape the future of the stock in bigger ways than the headlines show.

Read More »

Nvidia (NVDA) $5 Trillion Milestone Is Still Shaking Up Wall Street – Is This The Peak Of The AI Boom Or Just The Beginning?

After a period of unstoppable momentum, Nvidia (NVDA) is once again dominating headlines – and it’s no wonder Wall Street can’t look away. Once known primarily for gaming graphics, Nvidia has transformed itself into the beating heart of the AI revolution.

Its playbook, centered on innovation, scale, and ecosystem control, has turned the company into one of the most valuable and influential forces in tech history. But as investors cheer its meteoric rise, the question now looms: is Nvidia reaching new heights of sustainable growth, or is it flying too close to the sun?

Read More »

Netflix Stock (NFLX): Exciting 10:1 Split. Not-So-Exciting Earnings. What’s Under The Surface?

Netflix is one of the most recognizable companies in the world. It has a massive audience, strong brand awareness, and a long history of reshaping how we watch TV. Recently, Netflix announced a 10:1 stock split. A split does not change the value of the company, but it lowers the price per share and often makes the stock feel more accessible to everyday investors.

Read More »

Beyond Meat Stock (BYND) $900 Million Debt Deal News: Lifeline Or Last Gasp Before Collapse?

After months of steep declines and fleeting meme-fueled rallies, Beyond Meat (BYND) is once again in the spotlight – this time for its massive $900 million debt-for-equity deal. Once celebrated as the face of plant-based innovation, the company now finds itself fighting for survival amid collapsing sales, widening losses, and a heavily diluted shareholder base.

Read More »

Ferrari Stock (RACE) Plunged Hard. Is It A Short-Term Drop Or A Long-Term Decline?

Ferrari. A name that evokes speed, luxury, and precision.
But lately, its stock has been running into some rough turns.

After hitting record highs earlier this year, Ferrari’s share price took a sharp dive following its Capital Markets Day. Investors were caught off guard. Expectations were sky-high, and the company’s updated targets didn’t quite match the market’s adrenaline.

Read More »